keyword
MENU ▼
Read by QxMD icon Read
search

Everolimus AND aging

keyword
https://www.readbyqxmd.com/read/29778787/efficacy-of-palbociclib-combinations-in-hormone-receptor-positive-metastatic-breast-cancer-patients-after-prior-everolimus-treatment
#1
Ajay Dhakal, Christina M Matthews, Ellis Glenn Levine, Kilian Elizabeth Salerno, Fan Zhang, Kazuaki Takabe, Amy P Early, Stephen B Edge, Tracy O'Connor, Thaer Khoury, Jessica S Young, Mateusz Opyrchal
PURPOSE: Outcome data on hormone receptor positive (HR+ ), human epidermal growth factor receptor 2 (HER2) nonamplified (HER2- ) metastatic breast cancer (MBC) treated with palbociclib after treatment with everolimus are lacking. The PALOMA-3 trial, showing benefit of palbociclib plus fulvestrant compared to fulvestrant alone in HR+ HER2- MBC after progression while receiving endocrine therapy excluded women previously treated with everolimus. The objective of this study was to examine outcomes of HR+ HER2- MBC with prior exposure to everolimus while receiving palbociclib-based therapy...
April 28, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29774986/everolimus-drug-eluting-stent-performance-in-patients-with-long-coronary-lesions-the-multicenter-longprime-registry
#2
José Francisco Díaz Fernández, Santiago Jesús Camacho Freire, Juan Carlos Fernández Guerrero, Nicolas Delarche, Christophe Bretelle, Javier Zueco Gil, Ramón López Palop, Bruno García Del Blanco, Vicente Mainar Tello, Franck Albert
OBJECTIVES: To assess the efficacy and safety of the Xience Prime everolimus-eluting stent (EES) in long coronary lesions in a real-world population. BACKGROUND: Long lesions are considered difficult technically and in terms of achieving successful clinical outcomes. With first generation DES, MACE can be as high as 10% at a short-medium term follow-up. There are a few data available in this subset regarding the use of second generation DES METHODS: A prospective, multicenter registry of consecutive patients (aged 64...
May 18, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29774169/phase-2-study-of-everolimus-for-relapsed-or-refractory-classical-hodgkin-lymphoma
#3
Patrick B Johnston, Lauren C Pinter-Brown, Ghulam Warsi, Kristen White, Radhakrishnan Ramchandren
Background: The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) can improve progression-free survival (PFS). Novel therapies are required for patients refractory to chemotherapy and AHSCT. The mammalian target of rapamycin inhibitor everolimus has shown preliminary activity in preclinical models of HL and promising efficacy in patients with relapsed or refractory HL...
2018: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29739790/phase-ib-ii-study-of-second-line-therapy-with-panitumumab-irinotecan-and-everolimus-pie-in-kras-wild-type-metastatic-colorectal-cancer
#4
Amanda Townsend, Niall C Tebbutt, Christos S Karapetis, Pamela Cooper, Nimit Singhal, Sue J Yeend, Louise Pirc, Rohit Joshi, Jennifer Elizabeth Hardingham, Timothy Price
PURPOSE: Inhibition of mTOR in addition to EGFR may overcome resistance to EGFR inhibitors in metastatic colorectal cancer (mCRC). This phase Ib/II study evaluated the safety and efficacy of the combination of irinotecan, panitumumab and everolimus. EXPERIMENTAL DESIGN: Patients with KRAS exon 2 WT mCRC following failure of fluoropyrimidine based therapy received IV irinotecan and panitumumab every 2 weeks, and everolimus orally throughout a 14 day cycle. The primary endpoint of the phase II study was response rate (RR)...
May 8, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29727013/everolimus-dosing-recommendations-for-tuberous-sclerosis-complex-associated-refractory-seizures
#5
David N Franz, John A Lawson, Zuhal Yapici, Christian Brandt, Michael H Kohrman, Michael Wong, Mathieu Milh, Adelheid Wiemer-Kruel, Maurizio Voi, Neva Coello, Wing Cheung, Kai Grosch, Jacqueline A French
OBJECTIVE: The present analysis examined the exposure-response relationship by means of the predose everolimus concentration (Cmin ) and the seizure response in patients with tuberous sclerosis complex-associated seizures in the EXIST-3 study. Recommendations have been made for the target Cmin range of everolimus for therapeutic drug monitoring (TDM) and the doses necessary to achieve this target Cmin . METHODS: A model-based approach was used to predict patients' daily Cmin ...
May 4, 2018: Epilepsia
https://www.readbyqxmd.com/read/29699614/neoatherosclerosis-5-years-after-bioresorbable-vascular-scaffold-implantation
#6
Noriaki Moriyama, Koki Shishido, Yutaka Tanaka, Shohei Yokota, Takahiro Hayashi, Hirokazu Miyashita, Tatsuya Koike, Hiroaki Yokoyama, Takuma Takada, Takashi Nishimoto, Tomoki Ochiai, Kazuki Tobita, Futoshi Yamanaka, Shingo Mizuno, Masato Murakami, Saeko Takahashi, Shigeru Saito
BACKGROUND: Data regarding neoatherosclerosis after everolimus-eluting bioresorbable vascular scaffold (BVS) (ABSORB BVS Rev. 1.1, Abbott Vascular, Santa Clara, California) implantation are limited. OBJECTIVES: This study investigated the findings of neoatherosclerosis at 5 years after BVS 1.1 implantation by using multi-imaging modalities, including optical coherence tomography (OCT). METHODS: Patients included in the ABSORB EXTEND (ABSORB EXTEND Clinical Investigation) trial at Shonan Kamakura General Hospital underwent OCT at baseline after the index procedure and at 1 and 5 years...
May 1, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29662318/rare-malignant-insulinoma-with-multiple-liver-metastases-derived-from-ectopic-pancreas-3-year-follow-up-and-literature-review
#7
Qing Liu, Jianghui Duan, Yumin Zheng, Jie Luo, Xiaopin Cai, Huangying Tan
Here, we report the diagnosis and treatment of a very rare case of malignant insulinoma derived from ectopic pancreas. A middle-aged woman presented with a 6-year history of recurrent hypoglycemia with multiple lesions in liver. Admission workup revealed elevated serum insulin and C-peptide, as well as multiple lesions in the liver (largest being 4.3 cm), enlarged lymph nodes around the pancreas, and a lesion (of 3.5 cm) at the proximal jejunum, as shown by contrast computed tomography (CT). Liver biopsy showed the lesions to be well-differentiated neuroendocrine tumors, grade G1...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29643697/vascular-healing-response-after-everolimus-eluting-stent-implantation-in-acute-coronary-syndrome-culprit-lesions-comparison-with-implantation-in-stable-angina-pectoris
#8
Yutaka Goryo, Teruyoshi Kume, Tomoya Ueda, Makoto Watanabe, Ryotaro Yamada, Yoji Neishi, Yoshihiko Saito, Shiro Uemura
Background: To evaluate the neointimal conditions of everolimus-eluting stents (EESs) implanted in culprit lesions of patients with acute coronary syndrome (ACS) compared with stable angina pectoris (SAP) using optical coherence tomography (OCT). EESs are second-generation drug-eluting stents that have recently been shown to be useful in patients with ACS as well as in patients with SAP. However, few studies have analyzed the intra-stent conditions of EESs that can lead to favorable results in such ACS lesions...
March 2018: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/29589515/rheolytic-effects-of-left-main-mid-shaft-distal-stenting-a-computational-flow-dynamic-analysis
#9
Gianluca Rigatelli, Marco Zuin, Fabio Dell'Avvocata, Thach Nguyen
Background The aim of this study was to evaluate the rheolytic effects of stenting a mid-shaft/distal left main coronary artery (LMCA) lesion with and without ostial coverage. Stenting of the LMCA has emerged as a valid alternative in place of traditional coronary bypass graft surgery. However, in case of mid-shaft/distal lesion, there is no consensus regarding the extension of the strut coverage up to the ostium or to stent only the culprit lesion. Methods We reconstructed a left main-left descending coronary artery (LM-LCA)-left circumflex (LCX) bifurcation after analysing 100 consecutive patients (mean age 71...
March 1, 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29566104/everolimus-plus-endocrine-therapy-for-postmenopausal-women-with-estrogen-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-advanced-breast-cancer-a-clinical-trial
#10
Melanie Royce, Thomas Bachelot, Cristian Villanueva, Mustafa Özgüroglu, Sergio J Azevedo, Felipe Melo Cruz, Marc Debled, Roberto Hegg, Tatsuya Toyama, Carla Falkson, Joon Jeong, Vichien Srimuninnimit, William J Gradishar, Christina Arce, Antonia Ridolfi, Chinjune Lin, Fatima Cardoso
Importance: Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer. Objective: To investigate the combination of everolimus plus endocrine therapy in first-line and second-line treatment settings for postmenopausal women with estrogen receptor-positive, human epidermal growth receptor 2-negative advanced breast cancer. Design, Setting, and Participants: In the multicenter, open-label, single-arm, phase 2 BOLERO-4 (Breast Cancer Trials of Oral Everolimus) clinical trial, 245 patients were screened for eligibility; 202 were enrolled between March 7, 2013, and December 17, 2014...
March 22, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29556934/a-limited-sampling-strategy-to-estimate-exposure-of-everolimus-in-whole-blood-and-peripheral-blood-mononuclear-cells-in-renal-transplant-recipients-using-population-pharmacokinetic-modeling-and-bayesian-estimators
#11
Ida Robertsen, Jean Debord, Anders Åsberg, Pierre Marquet, Jean-Baptiste Woillard
BACKGROUND AND OBJECTIVE: Intracellular exposure of everolimus may be a better marker of therapeutic effect than trough whole blood concentrations. We aimed to develop pharmacokinetic population models and Bayesian estimators based on a limited sampling strategy for estimation of dose interval exposures of everolimus in whole blood and peripheral blood mononuclear cells (PBMCs) in renal transplant recipients. METHODS: Full whole blood and PBMC concentration-time profiles of everolimus were obtained from 12 stable renal transplant recipients on two different occasions, 4 weeks apart...
March 20, 2018: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29513378/incidence-and-predictors-of-target-lesion-failure-in-a-multiethnic-asian-population-receiving-the-synergy-coronary-stent-a-prospective-all-comers-registry
#12
Rajiv Ananthakrishna, William Kristanto, Li Liu, Siew-Pang Chan, Poay Huan Loh, Edgar L Tay, Koo Hui Chan, Mark Y Chan, Chi-Hang Lee, Adrian F Low, Huay Cheem Tan, Joshua P Loh
OBJECTIVES: To evaluate the target lesion failure (TLF) rate of the SYNERGY stent in all-comers, multiethnic Asian population. BACKGROUND: Currently, most drug eluting stents deliver anti-proliferative drugs from a durable polymer which is associated with a risk of late stent thrombosis. The novel everolimus-eluting, platinum chromium SYNERGY stent is coated with a bioabsorbable abluminal polymer that resolves within 4 months. METHODS: This was a prospective, single center registry of consecutive patients treated with the SYNERGY stent between December 2012 and April 2015...
March 7, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29508518/a-multicenter-post-marketing-evaluation-of-the-elixir-desolve-%C3%A2-novolimus-eluting-bioresorbable-coronary-scaffold-system-first-results-from-the-desolve-pmcf-study
#13
Holger Nef, Jens Wiebe, Niklas Boeder, Oliver Dörr, Timm Bauer, Karl-Eugen Hauptmann, Azeem Latib, Antonio Colombo, Dieter Fischer, Tanja Rudolph, Nicolas Foin, Gert Richardt, Christian Hamm
OBJECTIVES: To date, experience with bioresorbable scaffolds (BRS) that elute agents other than everolimus is limited. Thus, a post-marketing clinical follow-up study was conducted to evaluate the continued safety and effectiveness of the DESolve® NOVOLIMUS™ Eluting BRS as treatment for patients with stable coronary artery disease. BACKGROUND: The DESolve BRS combines a poly-l-lactide-based backbone with a biodegradable polylactide-based polymer and Novolimus, a macrocyclic lactone mTOR inhibitor...
March 6, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29500171/management-of-relapsed-refractory-classical-hodgkin-lymphoma-in-transplant-ineligible-patients
#14
REVIEW
Neha Mehta-Shah, Nancy L Bartlett
Addition of brentuximab vedotin, a CD30-targeted antibody-drug conjugate, and the programmed death 1 (PD-1) inhibitors nivolumab and pembrolizumab to the armamentarium for transplant-ineligible relapsed/refractory classical Hodgkin lymphoma has resulted in improved outcomes, including the potential for cure in a small minority of patients. For patients who have failed prior transplant or are unsuitable for dose-intense approaches based on age or comorbidities, an individualized approach with sequential use of single agents such as brentuximab vedotin, PD-1 inhibitors, everolimus, lenalidomide, or conventional agents such as gemcitabine or vinorelbine may result in prolonged survival with a minimal or modest effect on quality of life...
April 12, 2018: Blood
https://www.readbyqxmd.com/read/29484580/five-year-clinical-outcomes-of-everolimus-eluting-stents-from-the-post-marketing-study-of-cocr-ees-xience-v-promus-in-japan
#15
Jiro Aoki, Ken Kozuma, Masaki Awata, Mamoru Nanasato, Nobuo Shiode, Kengo Tanabe, Junichi Yamaguchi, Hajime Kusano, Hong Nie, Takeshi Kimura
The Cobalt Chromium Everolimus-Eluting Stent (CoCr-EES) Post Marketing Surveillance (PMS) Japan study is a prospective multicenter registry designed to evaluate the safety and efficacy of XIENCE V/PROMUS everolimus-eluting stents in routine clinical practice at 47 centers representative of the clinical environment in Japan. We enrolled 2010 consecutive patients (2649 lesions) who underwent percutaneous coronary intervention using CoCr-EES. Clinical outcomes were evaluated through 5 years. Mean age was 68.8 years, 41...
February 26, 2018: Cardiovascular Intervention and Therapeutics
https://www.readbyqxmd.com/read/29480592/breast-cancer-patients-have-increased-risk-of-developing-mtor-inhibitor-associated-stomatitis
#16
Mha de Lima, Gnm Hajj, Vcc de Lima, F A Alves
A total of 115 patients who used everolimus were evaluated. The mean age was 57 (±13.3) years old, and 87 patients were women (75.6%). mTOR inhibitor-associated stomatitis (mIAS) was observed in 36 patients (31.3%). The lesions ranged from 0.5 cm to 1.5 cm, and the tongue was the main site affected. In addition, 21 patients (58.3%) required a dose reduction of everolimus due to mIAS. Patients who had breast cancer presented 2.29-fold higher risk for developing mIAS when compared to patients with kidney or neuroendocrine tumors...
March 2018: Oral Diseases
https://www.readbyqxmd.com/read/29466966/real-life-patterns-of-care-and-progression-free-survival-in-metastatic-renal-cell-carcinoma-patients-retrospective-analysis-of-cross-sectional-data
#17
Rana Maroun, Laura Mitrofan, Laure Benjamin, Gaelle Nachbaur, Franck Maunoury, Philippe Le Jeunne, Isabelle Durand-Zaleski
BACKGROUND: Patient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with metastatic Renal Cell Carcinoma (mRCC) in a real world setting. METHODS: A retrospective analysis was performed using IQVIA real world oncology cross-sectional survey data, a retrospective treatment database collecting anonymized patient-level data in Europe...
February 21, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29454306/record-4-multicenter-phase-2-trial-of-second-line-everolimus-in-patients-with-metastatic-renal-cell-carcinoma-asian-versus-non-asian-population-subanalysis
#18
Lin Yang, Anna Alyasova, Dingwei Ye, Antonia Ridolfi, Luca Dezzani, Robert J Motzer
BACKGROUND: RECORD-4 assessed everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after 1 prior anti-vascular endothelial growth factor (VEGF) or cytokine and reinforced the clinical benefit of second-line everolimus. Because of the high percentage of patients from China enrolled in RECORD-4 (41%) and some reported differences in responses to certain targeted agents between Chinese and Western patients, this subanalysis evaluated outcomes in Asian versus non-Asian patients...
February 17, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29447735/new-onset-atrial-fibrillation-after-pci-or-cabg-for-left-main-disease-the-excel-trial
#19
Ioanna Kosmidou, Shmuel Chen, A Pieter Kappetein, Patrick W Serruys, Bernard J Gersh, John D Puskas, David E Kandzari, David P Taggart, Marie-Claude Morice, Paweł E Buszman, Andrzej Bochenek, Erick Schampaert, Pierre Pagé, Joseph F Sabik, Thomas McAndrew, Björn Redfors, Ori Ben-Yehuda, Gregg W Stone
BACKGROUND: There is limited information on the incidence and prognostic impact of new-onset atrial fibrillation (NOAF) following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD). OBJECTIVES: This study sought to determine the incidence of NOAF following PCI and CABG for LMCAD and its effect on 3-year cardiovascular outcomes. METHODS: In the EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial, 1,905 patients with LMCAD and low or intermediate SYNTAX scores were randomized to PCI with everolimus-eluting stents versus CABG...
February 20, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29413509/evaluation-of-the-clinical-characteristics-of-everolimus-induced-lung-injury-and-determination-of-associated-risk-factors
#20
Mitsuhiro Abe, Kenji Tsushima, Jun Ikari, Naoko Kawata, Jiro Terada, Nobuhiro Tanabe, Koichiro Tatsumi
BACKGROUND: Everolimus (ERL), a mammalian target of rapamycin (mTOR) inhibitor, has been used for the management of several advanced cancers. ERL frequently causes lung injury, although the clinical and radiographic features have not been clarified. The aim of this study was to assess the clinical features of ERL-induced lung injury and determine the associated risk factors. METHODS: This single-center, retrospective study included 45 patients (29 men, 16 women; age, 12-78 years) who had received ERL at our hospital between August 2010 and March 2016...
January 2018: Respiratory Medicine
keyword
keyword
50383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"